UX007 + Placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Conditions

Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Trial Timeline

Apr 19, 2017 → Oct 9, 2019

NCT ID

NCT02960217

About UX007 + Placebo

UX007 + Placebo is a phase 3 stage product being developed by Ultragenyx Pharmaceutical for Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS). The current trial status is terminated. This product is registered under clinical trial identifier NCT02960217. Target conditions include Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS).

What happened to similar drugs?

4 of 5 similar drugs in Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) were approved

Approved (4) Terminated (2) Active (1)

✅Exenatide + MetforminEli LillyApproved

✅Candesartan + PlaceboAstraZenecaApproved

✅Sitagliptin-Metformin + Metformin + Placebo pillMerckApproved

✅cyclosporine micro-emulsionNovartisApproved

🔄Ramipril + RosiglitazonePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02960217	Phase 3	Terminated	Apr 19, 2017	Oct 9, 2019	Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
NCT01993186	Phase 2	Completed	Feb 28, 2014	Sep 20, 2017	Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Competing Products

17 competing products in Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

See all competitors

Product	Company	Stage	Hype Score
Aspirin + Alpha lipoic acid + Olmesartan + Placebo	Daiichi Sankyo	Pre-clinical	26
Exenatide + Metformin	Eli Lilly	Approved	43
AZD1656	AstraZeneca	Phase 1	29
Candesartan + Placebo	AstraZeneca	Approved	35
Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg	Merck	Phase 2	35
Sitagliptin-Metformin + Metformin + Placebo pill	Merck	Approved	43
Comparator: exenatide + Comparator: exenatide + Comparator: Placebo	Merck	Phase 1	29
Placebo + Januvia	Merck	Phase 2	27
cyclosporine micro-emulsion	Novartis	Approved	35
Ramipril + Rosiglitazone	Pfizer	Phase 3	40
HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo	Haisco Pharmaceutical Group	Phase 2	35
Triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	20
UX007	Ultragenyx Pharmaceutical	Phase 2	21
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	25
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	29
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 2	29
GFT505 80mg + Placebo	Genfit	Phase 2	25